Also, Patel et al. (Patel et al., 2019) suggested that the combined administration of ruxolitinib and VSV-IFNβ therapy exhibited a promising trend towards enhanced mouse survival, while minimally impacting programmed death-ligand 1 (PDL-1) levels and immune infiltration within the tumor. This evidence concerns the gene CD274 and neoplasm.